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The multitarget iron chelator, M30, is a novel antioxidant and protective agent against oxidative stress in a spectrum of diseases.
However, there is no report regarding its role in liver diseases. Since oxidative stress is one of the major pathological events during
the progression of alcoholic liver diseases, the protective effects andmechanisms ofM30 on ethanol-induced hepatocyte injurywere
investigated in this study. Rat hepatocyte line BRL-3A was pretreated with M30 prior to ethanol treatment. Cell death, apoptosis,
oxidative stress, and inflammation were examined. Specific antagonists and agonists were applied to determine the involvements
of hypoxia inducible factor-1 alpha (HIF-1𝛼) and its upstream adenylate cyclase (AC)/cyclic AMP (cAMP)/protein kinase A
(PKA)/HIF-1𝛼/NOD-like receptor 3 (NLRP3) inflammasomepathway.We found thatM30 significantly attenuated ethanol-induced
cellular death, apoptosis, production of reactive oxygen species (ROS), and secretion of inflammatory cytokines and inhibited
activation of the AC/cAMP/PKA/HIF-1𝛼/NLRP3 inflammasome pathway. Inhibition and activation of the AC/cAMP/PKA/HIF-1𝛼
pathway mimicked and abolished the effects of M30, respectively. In conclusion, inhibition of the AC/cAMP/PKA/HIF-1𝛼/NLRP3
inflammasome pathway by M30 partially contributes to its attenuation of hepatocyte injury caused by ethanol exposure.
1. Introduction
Alcoholic liver diseases (ALDs), including acute alcoholic
liver injury, liver failure, alcoholic fatty liver disease (AFLD),
and alcoholic steatohepatitis (ASH), annually result in an
estimated 2.5 million deaths (4% of all mortality) world-
wide [1]. Alcoholism or alcohol use disorder is defined as
overconsumption of ethanol (men > 30 g/day and women >
20 g/day) [2]. The only definitive clinical treatment for ALD
is liver transplantation. Abstinence is critical but usually
cannot reverse advanced ALD. It should be accompanied by
supportive therapy and nutritional management [3]. To date,
although a spectrum of key signaling pathways and thera-
peutic targets have been described in ALD, the interaction
between oxidative stress and inflammation is considered to be
a central event during the initiation and progression of ALD
[4, 5].
Inflammasomes are a group of large caspase-1-activating
protein complexes in response to the evocation of innate
immunity and the production of proinflammatory cytokines,
interleukin-1𝛽 (IL-1𝛽), and IL-18. Inflammasome activation
has been shown to induce cell pyroptosis, a process of
programmed cell death distinct from apoptosis [6]. Inflam-
masomes, particularly NOD-like receptor 3 (NLRP3) inflam-
masome, are shown to be activated in a variety of acute
and chronic liver diseases, including ALD [7]. Our previous
study found that Lycium barbarum polysaccharide atten-
uated ethanol-induced hepatocyte injury partially through
regulating the thioredoxin-interacting protein- (TXNIP-)
NLRP3 inflammasome pathway [7]. However, the upstream
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regulators of NLRP3 during ALD progression await further
investigation.
Hypoxia-inducible factor-1 alpha (HIF-1𝛼) is activated by
hypoxia and is a master regulator of cellular redox status and
downstream production of proinflammatory cytokines (e.g.,
tumor necrosis factor-alpha (TNF-𝛼) and IL-6) [8]. It could
be activated by increased cellular oxygen levels, primarily at
the protein level [9]. Recent studies pointed out that under
hypoxic or oxidative stress environments, adenylate cyclase
(AC) activates HIF-1𝛼 through cyclic AMP (cAMP)/protein
kinase A (PKA) pathway [10]. Since ethanol induces hypoxia
and elevates HIF-1𝛼 in the liver [11], it was speculated that
HIF-1𝛼 might be a novel therapeutic target for ethanol-
induced injury and an upstream regulator of NLRP3 inflam-
masome.
In the current study, we aimed to determine whether the
AC/cAMP/PKA/HIF-1𝛼 pathway andNLRP3 inflammasome
are involved in the protective effect of a novel multitarget iron
chelator (M30) against ethanol-induced hepatocyte injury in
vitro.
2. Materials and Methods
2.1. Drugs and Chemicals. Themultifunctional iron chelator,
M30 (5-[N-methyl-N-propargylaminomethyl]-8-hydroxy-
quinoline) was synthesized and kindly provided by Varinel
Inc. (Philadelphia, PA) [12, 13]. CAY10585 (HIF-1𝛼 inhibitor)
was purchased from Cayman Chemical (Ann Arbor, MI).
Forskolin (AC agonist), SQ22536 (AC inhibitor), H89 (PKA
inhibitor), and db-cAMP (stable cAMP analogue) were
purchased from Sigma-Aldrich (St. Louis, MO). Antibodies
against catalase (CAT), glutathione peroxidase 1 (GPx1),
NLRP3, apoptosis-associated speck-like protein containing
a CARD (ASC), caspase-1, and 𝛽-actin were ordered from
Abcam (Cambridge, UK).
2.2. Cell Culture and Treatments. Rat normal hepatocyte cell
line BRL-3A was supplied by the Cell Bank of Type Cul-
ture Collection of Chinese Academy of Sciences (Shanghai,
China). Cells were cultured in DMEM with 10% (v/v) FBS at
37∘C with 5% CO
2
. Before drug treatment, cells must reach
a confluence of 60–70%. For the pretreatment with M30,
PBS dissolved M30 was added 2 hours before the ethanol
treatment. For the treatments using agonists and inhibitors
of the AC/cAMP/PKA/HIF-1𝛼 pathway, drugs were added
along with M30 or individually 2 hours before the ethanol
treatment at designated concentrations.
2.3. MTT Assay. The cell viability was evaluated by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT, Sigma-Aldrich, St. Louis, MO) method. After drug
treatment, cells were washed by sterile PBS for 3 times
and then incubated with 5mg/mL MTT for 3 hours and
subsequently dissolved in dimethyl sulfoxide (DMSO). The
absorbance of cells was measured at 570 nm. The percent of
cell viability was defined as the relative absorbance of treated
cells versus untreated cells.
2.4. Detection of Alanine Aminotransferase (ALT) Levels.
After treatments, cell supernatant was collected and the level
of ALT was detected by an ALT/GPT kit (EIAab Science,
Wuhan, China) according to manufacturer’s instruction.
2.5. Quantification of Apoptotic Cells. After treatment,
Hoechst 33342 (Sigma, 5 𝜇g/mL) and propidium iodide
(Sigma, 5 𝜇g/mL) were added to each well to stain live cells.
The cell population was separated into 3 groups: live cells
showed only a low level of fluorescence; apoptotic cells
showed a higher level of blue fluorescence; and dead cells
showed low-blue and high-red fluorescence. Stained cells
were observed and quantified by two independent cell
biologists without knowing the grouping. The results were
expressed as the percentage of apoptosis (PA): PA = apoptotic
cell number/total cell number × 100% [14].
2.6. Caspase-3/7 Activity. The activity of caspase-3/7 in cell
lysate was measured using the Cell Meter Caspase-3/7 Activ-
ity Apoptosis Assay Kit (AAT Bio., Sunnyvale, CA) according
to the user manual. The results were read at 520 nm in a
microplate reader (Bio-Rad) and expressed as fold change of
the control.
2.7. Measurement of ROS Production. Intracellular produc-
tion of ROS was detected by a fluorescence probe—2󸀠,7󸀠-
dichlorofluorescin diacetate (DCFH-DA, Sigma-Aldrich), as
previously described [7]. Briefly, after treatment, cells were
washed three times with PBS and then incubated with 10 𝜇M
DCFH-DA for 30min at 37∘C for green fluorescent light visu-
alization. Quantification of green fluorescence was analyzed
by using ImageJ software (Version 1.48, National Institutes
of Health, Bethesda, MD). Fluorescent quantification results
were then normalized by the protein amount of each specific
plate well (∼110–150 𝜇g/well of a 24-well plate).
2.8. GSH/GSSG Ratio Measurement. To determine the intra-
cellular oxidative status, the ratio of reduced glutathione
(GSH) to oxidized glutathione (GSSG) in each cellular pro-
tein sample was measured by using a GSH/GSSG detection
assay kit from Abcam (Cambridge, UK).
2.9. RNA Extraction and Quantitative PCR. Total cellular
RNA was extracted using illustra RNAspin mini kit (GE
healthcare, UK). The preparation of the first-strand cDNA
was conducted following the instruction of the SuperScript
First-Strand Synthesis System (Invitrogen, Carlsbad, CA).
The mRNA expression levels of target genes were mea-
sured by Takara SYBR premix Taq quantitative PCR system
(Takara Bio Inc., Shiga, Japan) and in MyiQ2 real-time PCR
machine (Bio-Rad, Hercules, CA). Parallel amplification of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
used as an internal control. Relative quantification was
calculated using the 2−ΔΔCt method. Primers and PCR condi-
tions were described in previous literature [15]. The relative
expression of the specific gene to the internal control was
obtained and then expressed as percentage of the control
value. All real-time PCR procedures including the design of
Oxidative Medicine and Cellular Longevity 3
EtOH (250 mM) −
−
−
+
−
−
−
−
+
−
+
−
+
−
+
+
−
+
0
20
40
60
80
100
120
C
el
l v
ia
bi
lit
y 
(%
ct
rl)
## ##
∗∗∗
M30 (0.5 𝜇M)
M30 (5𝜇M)
24h
48h
(a)
0
5
10
15
20
25
Ctrl EtOH M30 E + M30
A
LT
 le
ve
l (
U
I/L
)
##
∗∗∗
(b)
Figure 1: M30 improved hepatocytes injury. (a) Cell viability after 24-hour and 48-hour treatments and (b) released ALT concentration in
the culture medium. Data from each group (𝑛 = 4) were expressed as means ± SEM. Statistical comparison between groups was done using
the Kruskal-Wallis test followed by Dunn’s post hoc test to detect differences in all groups. “∗ ∗ ∗” means significantly different from control
group (𝑃 < 0.001). “##” means significantly different from ethanol exposure group (𝑃 < 0.01). “###” means significantly different from
ethanol exposure group (𝑃 < 0.001). EtOH, ethanol, M30, vehicle M30 treatment, E + M30, ethanol + M30 cotreatment.
primers, validation of PCR environment, and quantification
methods were performed following the MIQE guideline [16].
2.10. Western Blot. Western blot analyses of cell lysates
(cytosolic or nuclear fractions) were performed as previously
described [17]. The ratio of the optical density of the protein
product to the internal control (𝛽-actin) was obtained and the
data were expressed as ratio or percentage of the control.
2.11. Enzyme-Linked Immunosorbent Assay (ELISA) Assay.
The levels of secreted TNF-𝛼, IL-1𝛽, and IL-6 in culture
medium were measured using corresponding ELISA kits
from PeproTech (PeproTech Inc., Rocky Hill, NJ) according
to user instructions. ELISA assay kit for secreted IL-18
was purchased from Invitrogen (Carlsbad, CA). The level
of HIF-1𝛼 was measured using an EIISA kit from Abcam
(Cambridge, UK).
2.12. Statistical Analysis. Data were expressed as means ±
SEM. Comparison between groups was examined using the
Kruskal-Wallis test followed by Dunn’s post hoc test. A value
of 𝑃 < 0.05 was considered to be statistically significant
(Prism 5.0, Graphpad software, Inc., San Diego, CA).
3. Results
3.1. M30 Inhibited Ethanol-Induced Hepatocyte Injury and
Apoptosis. Based on previous literatures [18, 19], we selected
0.5 𝜇Mand 5 𝜇MM30 in the current study. Cell viability assay
suggested that, after 24-hour exposure to ethanol, around
30% of BRL-3A cells became inviable. M30 pretreatment at
both concentrations significantly increased the cell viability
(Figure 1(a)). A 48-hour treatment with ethanol and/or M30
exhibited similar results, indicating that the protective effects
of M30 on ethanol-damaged hepatocyte mainly occurred
within the first 24 hours (Figure 1(a)). Therefore, we selected
0.5 𝜇M and 24 hours as the incubation concentration and
duration for the following studies. In line with the cell
viability results, pretreatment with 0.5 𝜇M M30 significantly
reduced ethanol exposure caused release of ALT from dam-
aged hepatocyte into the culture medium (Figure 1(b)).
To examine the effects of M30 on cellular apoptosis, we
firstly measured the apoptotic ratio of BRL-3A after various
treatments.We found that ethanol exposure greatly increased
apoptosis of the cell, from ∼2% to ∼18% (∼9-fold) and
pretreatment of M30 partially abolished this effect of ethanol
(Figure 2(a)). Quantification of cellular caspase-3/7 activity,
antiapoptotic gene Bcl-2, and proapoptotic gene Bax1 further
supported these observations (Figures 2(b) and 2(c)).
3.2. M30 Inhibited Ethanol-Induced Hepatocyte Oxidative
Stress. Since formation of ROS and oxidative stress are main
consequences of ethanol metabolism in the hepatocytes, we
then tested the production of ROS in the culture medium
and within the hepatocyte after ethanol and/or M30 incu-
bation. Fluorescence staining results suggested that ethanol
obviously increased the signal of ROS staining, while M30
reduced it (Figures 3(a) and 3(b)). This phenomenon was
consistentwith the finding that ethanol exposure significantly
reduced the protein expression level of antioxidant enzymes
CAT and GPx1, which was recovered by the pretreatment
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Figure 2:M30 improved cellular apoptosis. (a) Apoptotic ratio after various treatments. (b)Activity of caspase-3/7 of hepatocytes after various
treatments. (c) Cellular Bcl-2 and Bax1 mRNA change after various treatments. Data from each group (𝑛 = 4) were expressed as means ±
SEM. Statistical comparison between groups was done using the Kruskal-Wallis test followed by Dunn’s post hoc test to detect differences in
all groups. “∗” means significantly different from control group (𝑃 < 0.05). “∗∗” means significantly different from control group (𝑃 < 0.01).
“∗∗∗”means significantly different from control group (𝑃 < 0.001). “#”means significantly different from ethanol exposure group (𝑃 < 0.05).
“##” means significantly different from ethanol exposure group (𝑃 < 0.01). “###” means significantly different from ethanol exposure group
(𝑃 < 0.001). EtOH, ethanol, M30, vehicle M30 treatment, E + M30, ethanol + M30 cotreatment.
with M30 (Figure 3(c)). In addition, the status change of
cellular oxidative stress was exhibited by the ratio change
of cellular GSH/GSSG, since this ratio is an indicator of
cellular health, with reduced GSH constituting up to 98%
of cellular GSH under normal conditions [20]. Ethanol
treatment significantly reduced the GSH/GSSG ratio from
∼2.9 to ∼1.2. Pretreatment with M30, either independently
or in combination with ethanol, significantly increased the
ratio to a level (∼4.7) even higher than that of the control
group, strongly suggesting the antioxidant property of M30
(Figure 3(d)). We also quantified the activity of HIF-1𝛼, one
of the major regulators of oxidative stress generation in
alcoholic liver diseases [9]. In agreement with other studies,
ethanol significantly induced the activity of HIF-1𝛼, which
was reversed by the pretreatment with M30. Vehicle-M30
treatment did not influence the basal activity level of HIF-1𝛼
(Figure 3(e)).
3.3. M30 Attenuated Ethanol-Induced Hepatocyte Inflam-
matory Responses and NLRP3 Inflammasome Activation.
Overproduction of ROS and oxidative stress in the liver
after ethanol exposure often induce potent inflammatory
responses, which may significantly aggravate the pathogene-
sis of ALD [21].Thus, whether pretreatmentwithM30 attenu-
ates ethanol-induced proinflammatory cytokines production
and NLRP3 inflammasome activation is another important
aim for the current study. ELISA results of secreted TNF-
𝛼 and IL-6 showed that ethanol incubation greatly induced
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Figure 3:M30 improved cellular oxidative stress. (a) Production of ROS staining in the cells after various treatments (magnification 200x, bar
= 100𝜇m). (b) Quantification of ROS staining. (c) Expressional changes of antioxidants CAT and GPx1 after various treatments. (d) Change
of GSH/GSSG ratio treatments. (e) Changes of transcriptional activity of HIF-1𝛼 in each group. Data from each group (𝑛 = 4) were expressed
as means ± SEM. Statistical comparison between groups was done using the Kruskal-Wallis test followed by Dunn’s post hoc test to detect
differences in all groups. “∗” means significantly different from control group (𝑃 < 0.05). “∗∗” means significantly different from control
group (𝑃 < 0.01). “∗ ∗ ∗” means significantly different from control group (𝑃 < 0.001). “##” means significantly different from ethanol
exposure group (𝑃 < 0.01). “###” means significantly different from ethanol exposure group (𝑃 < 0.001). Letters “a” labelled above the values
of control, M30, and ethanol + M30 groups mean there is no significant change among these groups (𝑃 > 0.05). Letter “b” means the value
of ethanol-treated group is statistically different from other three values (𝑃 < 0.05). EtOH, ethanol, M30, vehicle M30 treatment, E + M30,
ethanol + M30 cotreatment.
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the secretion of these two proinflammatory cytokines from
BRL-3A cells, indicating an inflammatory status of the cells.
M30 totally or partially abolished such effects (Figures 4(a)
and 4(b)). This phenomenon was further confirmed by
the change of transcription activity of NF-𝜅B, the master
regulator of both oxidative stress and inflammation in the
liver (Figure 4(c)). To characterize the involvement of NLRP3
inflammasome in ethanol-induced hepatocyte damage and
M30-mediated protection, the cellular protein levels of
NLRP3, ASC, and caspase-1, as well as the secreted protein
levels of both IL-1𝛽 and IL-18, were measured by Western
blot or ELISA in all groups. Ethanol exposure significantly
upregulated all the protein levels of these key components
of NLRP3 inflammasome, indicating that NLRP3 inflamma-
some was activated during ethanol incubation. Pretreatment
with M30 significantly reduced their levels (Figures 4(d)–
4(f)).
3.4. Inhibition of HIF-1𝛼 Reduced NLRP3 Inflammasome
Activation. The production of IL-1𝛽 is a central step in ALD
progression. Thus, delineating the upstream signals that
lead to the activation of NLRP3 inflammasome and IL-1𝛽
secretion is important for the pathological study of this
disease [22, 23]. Since recent several reports suggested that
there were HIF-1𝛼 response elements in the human and
mouse Il1b promoter [24], it was interesting to find whether
blockade of HIF-1𝛼 could reduce the production of IL-1𝛽 and
other inflammasome products (IL-18 and caspase-1) in our
system. The HIF-1𝛼 inhibitor CAY10585 was able to signif-
icantly decrease ethanol induced IL-1𝛽 production without
affecting its basal level (Figure 5(a)). Addition ofM30 further
reduced the production of IL-1𝛽 to a control-comparable
level, indicating that HIF-1𝛼 was indeed a regulating target
of M30, but there should be other targets that M30 used to
play its protective roles against ethanol (Figure 5(a)). Change
of IL-18 and caspase-1 protein level further confirmed this
observation (Figures 5(b) and 5(c)).
3.5. M30 Modulates AC/cAMP/PKA Pathway and Its Down-
stream HIF-1𝛼. Since PKA activates HIF-1𝛼 through cAMP
response element-binding protein (CREB) [25] and AC is
reported to be the target of other hepatoprotective agents
[26], we then considered that the AC/cAMP/PKA pathway
might be repressed by M30 to downregulate the activity of
HIF-1𝛼. To test this hypothesis, AC activator forskolin and
inhibitor SQ22536 were used to treat BRL-3A cells in the
presence or absence of ethanol and M30. We found that
vehicle forskolin slightly increased the basal secretion of IL-
1𝛽 but not IL-18. When pretreated with M30 before ethanol,
forskolin significantly reduced the effect of M30 on IL-1𝛽
and IL-18 secretion. Similarly, when AC was inhibited by
SQ22536, the secretion of IL-1𝛽 and IL-18 induced by ethanol
exposure was significantly decreased (Figures 6(a) and 6(b)).
Pretreatment with SQ22536 before ethanol potentiated the
effect of M30 on the reduction of IL-1𝛽 and IL-18 secretion.
Collectively, these data suggested that M30 exerted its ben-
eficial effects on hepatocytes partially through the action of
AC.
We then used a stable analogue of cAMP (db-cAMP) and
an inhibitor of PKA (H89) to see the change of IL-1𝛽 and
IL-18 secretion in our system. In line with the results from
AC overactivation and repression, db-cAMP significantly
impaired the effects ofM30 on both IL-1𝛽 and IL-18 secretion
whileH89 partiallymimicked the effects ofM30 (Figures 6(c)
and 6(d)), indicating that the cAMP/PKA pathway was also
applied by M30 when treating alcoholic hepatocyte injury.
4. Discussion
M30 is one of the most effective drugs possessing iron-che-
lating/radical scavenging potency and inhibition of lipid per-
oxidation features. Cytochrome P450 isoenzyme inhibition
and voltage-dependent potassium channel blocking studies
showed that M30 was not cytotoxic in several cell lines
[12, 13]. M30 has been shown to inhibit oxidative stress and
inflammation in several diseases, including type 2 diabetes
mellitus [27], Alzheimer’s disease [28], Parkinson’s disease
[29], and drug-induced brain cell injury [30]. However,
little is known about its effect on the liver. In this study,
we demonstrated that pretreatment with M30 significantly
preserved cell viability, attenuated cell damage, and improved
cellular oxidative stress and inflammation in an in vitro
ethanol-induced hepatocyte injury model. Pharmacological
activation and inhibition by specific agonist and inhibitors
of signaling molecules further confirmed the partial involve-
ment of the AC/cAMP/PKA/HIF-1𝛼 and the NLRP3 inflam-
masome pathways in the hepatoprotective actions of M30.
A number of previous papers reported that ethanol
evoked HIF-1𝛼 activation in the liver. For example, ethanol
treatment induced fatty liver was alleviated in mice with
hepatocyte-specifically knockdown of HIF-1𝛼, while overex-
pression of HIF-1𝛼 aggravated that damage [31]. Wang et al.
also found that blocking HIF-1𝛼 activation and subsequent
action had therapeutic implication against ethanol/CYP2E1-
induced oxidative stress, steatosis, and liver injury [11]. In
our study, after ethanol exposure, the activity of HIF-1𝛼 was
significantly increased along with exacerbated hepatocyte
damage, oxidative stress, inflammation, and NLRP3 inflam-
masome activation when compared with those in the con-
trol group. M30 pretreatment significantly reduced HIF-1𝛼
activity and other cellular injuries. Correspondingly, ethanol-
induced NLRP3 inflammasome activation was decreased in
cells treated with HIF-1𝛼 inhibitor CAY10585. M30 addition
further reduced the inflammasome activation. Collectively,
these data suggested that HIF-1𝛼 might play important roles
in ethanol-induced hepatocyte injury and M30-mediated
hepatoprotection. This conclusion was consistent with a
very recent paper finding that moderate hypoxia potentiates
NLRP3 inflammasome activation and IL-1𝛽 production in
activated humanmacrophages [32]. Opposite to our findings,
several previous studies suggested that M30 could ameliorate
neuronal oxidative stress through the stabilization and induc-
tion of HIF-1𝛼 protein.This may be attributed to the different
downstream signalings in different organs (brain versus liver)
[27–29]. Indeed, further studies are warranted to delineate
this discrepancy.
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Figure 4: M30 improved cellular inflammation and NLRP3 inflammasome activation. (a, b) Changes of secreted levels of TNF-𝛼 and IL-6
in each group after treatments. (c) Change of transcriptional activity of NF-𝜅B p65 subunit after treatments. (d) Expressional changes of
NLRP3, ASC, and caspase-1 proteins after treatments. (e, f) Changes of secreted levels of IL-1𝛽 and IL-18 in each group after treatments.
Data from each group (𝑛 = 4) were expressed as means ± SEM. Statistical comparison between groups was done using the Kruskal-Wallis
test followed by Dunn’s post hoc test to detect differences in all groups. “∗” means significantly different from control group (𝑃 < 0.05).
“∗∗” means significantly different from control group (𝑃 < 0.01). “∗ ∗ ∗” means significantly different from control group (𝑃 < 0.001).
“#” means significantly different from ethanol exposure group (𝑃 < 0.05). “##” means significantly different from ethanol exposure group
(𝑃 < 0.01). “###” means significantly different from ethanol exposure group (𝑃 < 0.001). Letters “a” labelled above the values of control, M30,
and ethanol + M30 groups mean there is no significant change among these groups (𝑃 > 0.05). Letter “b” means the value of ethanol-treated
group is statistically different from other three values (𝑃 < 0.05). For NLRP3 protein, letter “c” on ethanol + M30 group means significant
change when compared with other three groups (i.e., control, ethanol, and M30, 𝑃 < 0.05). EtOH, ethanol, M30, vehicle M30 treatment, E +
M30, ethanol + M30 cotreatment.
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Figure 5: HIF-1𝛼 is critical for theNLRP3 inflammasome activation. (a–c) Changes of secreted IL-1𝛽, IL-18, and cellular caspase-1 expressions
after ethanol exposure, M30 pretreatment, and/or HIF-1𝛼 inhibitor CAY10585. Data from each group (𝑛 = 4) were expressed as means ±
SEM. Statistical comparison between groups was done using the Kruskal-Wallis test followed by Dunn’s post hoc test to detect differences in
all groups. “∗” means significantly different from control group (𝑃 < 0.05). “∗∗” means significantly different from control group (𝑃 < 0.01).
“∗∗∗”means significantly different from control group (𝑃 < 0.001). “#”means significantly different from ethanol exposure group (𝑃 < 0.05).
“##” means significantly different from ethanol exposure group (𝑃 < 0.01). “###” means significantly different from ethanol exposure group
(𝑃 < 0.001).
The direct link between the AC/cAMP/PKA pathway and
the activation of HIF-1𝛼 has been recently examined in sev-
eral cell models, such as epithelial-mesenchymal transition in
lung cancer [33], pancreatic beta cell injury [34], and inflam-
mation in macrophage [10]. We demonstrated that activation
and inhibition of the AC/cAMP/PKA pathway could, respec-
tively, increase and decrease the production of inflammasome
products (IL-1𝛽 and IL-18). Indeed, the signaling mediator
in the upstream of AC (particularly the membrane receptor)
that immediately transduces ethanol-induced damage and
M30-mediated protection is the key missing link for the
current study. Based on the studies that adenosine 1A or
2A receptor antagonist prevented and reversed liver injury
in mouse models of ALD [35, 36] and that adenosine
2A receptor directed the activation of NLRP3 inflamma-
some through the AC/cAMP/PKA/HIF-1𝛼 pathway [10],
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Figure 6: Role of the AC/cAMP/PKA pathway in NLRP3 inflammasome activation. (a-b) Changes of secreted IL-1𝛽 and IL-18 after ethanol
exposure, M30 pretreatment, and/or AC agonist forskolin/inhibitor SQ22536. (c-d) Changes of secreted IL-1𝛽 and IL-18 after ethanol
exposure,M30 pretreatment, and/or cAMP analogue db-cAMP/PKA inhibitor H89. Data from each group (𝑛 = 4) were expressed asmeans ±
SEM. Statistical comparison between groups was done using the Kruskal-Wallis test followed by Dunn’s post hoc test to detect differences in
all groups. “∗” means significantly different from control group (𝑃 < 0.05). “∗∗” means significantly different from control group (𝑃 < 0.01).
“∗∗∗”means significantly different from control group (𝑃 < 0.001). “#”means significantly different from ethanol exposure group (𝑃 < 0.05).
“##” means significantly different from ethanol exposure group (𝑃 < 0.01). “###” means significantly different from ethanol exposure group
(𝑃 < 0.001).
we highly speculated that adenosine receptors could be the
key immediate molecules modulating the beneficial effects of
M30. This hypothesis deserves future investigations.
In conclusion, pretreatment with multitarget iron chela-
tor and antioxidant M30 attenuates ethanol-induced injury
in rat BRL-3A hepatic cells. The hepatoprotective property
of M30 is partially achieved by modulating the AC/cAMP/
PKA/HIF-1𝛼 pathway.This study also provides a rationale for
developing hepatoprotective therapies that target HIF-1𝛼 or
its up/downstream mediators.
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